Although widespread adoption of continuous bioprocessing has been slow, some processes have been an exception.
Kathleen A. Estes
Advertisement
Kathleen A. Estes, PhD, is director of research communications atBioPlan Associates, Inc. She is an experienced market research and data trends analyst, author, and editor, kestes@bioplanassociates.com.
Articles by Kathleen A. Estes
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
2
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
3
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
4
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
5